Skip to main content

Test Price

2,800 AED

โœ… Home Collection Available

IL11RA Gene Craniosynostosis and Dental Anomalies Genetic Test in UAE | 2800 AED | DHA Licenced

Executive Summary & Core Metrics

Executive Summary

The IL11RA gene sequencing test employs Next Generation Sequencing (NGS) technology to detect pathogenic variants linked to syndromic craniosynostosis and dental anomalies, delivering definitive molecular diagnosis with 99.9% diagnostic sensitivity. The test is processed at DNA Labs UAE, a DHA-licensed facility (License No. 1143) operating under ISO 9001:2015 accreditation. All procedures comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning health data security.

  • Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited NGS Processing.
  • Premium Logistics: VIP Mobile Phlebotomy and Temperature-Controlled Cold-Chain Home Collection available daily 8 AM to 11 PM.
  • Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by a Consultant Medical Genetics specialist.
  • Insurance: Direct Billing Verification available via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This advanced molecular genetic test screens the entire coding region of the IL11RA gene for pathogenic and likely pathogenic variants associated with syndromic craniosynostosis and dental anomalies. The NGS methodology provides comprehensive coverage of all exons and flanking intronic regions, enabling detection of novel variants that single-gene Sanger sequencing may miss. Clinical correlation with phenotype and family history is essential for accurate interpretation.

Feature Our IL11RA NGS Test Closest Alternative (Single-Gene Sanger)
Precision99.9% sensitivity / full gene sequencingOnly known mutation hot spots, lower sensitivity
MethodologyNext Generation Sequencing (NGS) | ISO 9001:2015Sanger sequencing
Turnaround3 to 4 Weeks6โ€“8 Weeks
Price2800 AEDVariable; often higher

Physician Insight & Safety Protocols

Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: โ€œA positive IL11RA result confirms the clinical suspicion and guides timely multidisciplinary craniofacial and dental care. It is essential to correlate the molecular finding with the patientโ€™s phenotype and family historyโ€”never discontinue prescribed treatments based solely on this test.โ€

Advisory Notice

๐Ÿ”ด Medication Warning

Do not stop or alter any prescribed medication regimen without explicit guidance from your treating physician. This genetic test provides diagnostic information and is not a substitute for ongoing clinical management or emergency medical care. Always consult your healthcare provider before making treatment decisions based on test results.

Safety Exclusion Criteria & Emergency Indicators

  • Test not indicated for individuals with a confirmed non-IL11RA syndromic diagnosis.
  • Emergency Red Flags: If the patient develops a bulging fontanelle, persistent projectile vomiting, downward eye deviation (sunset sign), or acute lethargy, seek immediate ER careโ€”do not delay for genetic test results.
  • Home phlebotomy will be rescheduled if the patient is febrile or on anticoagulants that cannot be safely interrupted.

Patient FAQ & Clinical Guidance

1. What is the IL11RA gene test and how does it work?

The IL11RA gene test uses Next Generation Sequencing to detect mutations causing craniosynostosis and dental anomalies with 99.9% accuracy. The test analyses the entire coding region of the IL11RA gene for pathogenic variants, providing a definitive molecular diagnosis that informs surgical and dental management planning.

2. Who should consider this test?

Infants with abnormal head shape, delayed fontanelle closure, or dental eruption issues should be evaluated by a paediatrician or clinical geneticist for potential IL11RA-related craniosynostosis. Genetic counselling prior to testing is strongly recommended to ensure informed consent and appropriate interpretation of results.

3. How is the sample collected and what is the turnaround time?

A standard peripheral blood sample is collected via VIP Mobile Phlebotomy at your home or at our Dubai Healthcare City facility. The sample is transported under temperature-controlled cold-chain logistics to our ISO-accredited laboratory. Results are available within 3 to 4 weeks.

4. What are the pre-requirements for this test?

A detailed clinical history is mandatory, including a pedigree chart of family members affected by craniosynostosis or dental anomalies. Genetic counselling prior to testing is strongly recommended to ensure informed consent and accurate result interpretation. For minors, additional consent requirements under UAE PDPL and Federal Law No. 2 of 2019 apply.

5. How does this test compare to alternative testing methods?

Our NGS-based test offers 99.9% sensitivity across the full gene sequence, compared to Sanger sequencing which only targets known mutation hot spots. The NGS approach also delivers faster turnaround (3โ€“4 weeks vs 6โ€“8 weeks) at a competitive price of 2800 AED.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance Framework:

  • Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) โ€“ governs the collection, processing, and storage of personal health data.
  • Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields โ€“ establishes security standards for electronic health information.
  • Federal Decree-Law No. 4 of 2016 on Medical Liability โ€“ defines clinical safety and patient consent requirements for genetic testing.
  • DHA Facility License No. 1143 โ€“ DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority.
  • ISO 9001:2015 โ€“ Laboratory quality management system certified under INT/EGQ/2509DA/3139.

Clinical & Logistical Metadata

Test Name IL11RA Gene Craniosynostosis and Dental Anomalies Genetic Test (NGS)
Price (AED) 2800 AED
Turnaround Time 3 to 4 Weeks
Sample Type / Matrix Peripheral Whole Blood (EDTA) or FTA Card
Methodology Used Next Generation Sequencing (NGS) โ€“ Full Gene Coding Region Analysis
ICD-10-CM Code Q75.0 (Craniosynostosis)
LOINC Code 55233-1 (Genetic analysis)
DHA Facility License & Laboratory Address DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE

ุฏุนู… ุซู†ุงุฆูŠ ุงู„ู„ุบุฉ ู…ุชุงุญ

ุงู„ุชุญู‚ู‚ ู…ู† ุงู„ุชุบุทูŠุฉ ุงู„ุชุฃู…ูŠู†ูŠุฉ

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

ุชูˆู‚ู ุนู† ุงู„ุชุฎู…ูŠู†. ุฃุฑุณู„ ุตูˆุฑุฉ ู…ู† ุจุทุงู‚ุฉ ุงู„ุชุฃู…ูŠู† ูˆูˆุตูุฉ ุงู„ุทุจูŠุจ ุฅู„ู‰ ูุฑูŠู‚ ุงู„ุชุญู‚ู‚ ุงู„ู…ุนุชู…ุฏ ู…ู† ู‡ูŠุฆุฉ ุงู„ุตุญุฉ ุจุฏุจูŠ ุนุจุฑ ุงู„ูˆุงุชุณุงุจ. ุงุญุตู„ ุนู„ู‰ ุชุญุฏูŠุซ ุงู„ุญุงู„ุฉ ููŠ ุฏู‚ุงุฆู‚.

โœ… DHA Certified โœ… ISO 15189 โœ… HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

๐Ÿ…

ISMS 27001:2022

๐Ÿ“‹

ISO Accredited

๐Ÿ”’

HIPAA

All reports reviewed by DHA-Certified physicians